Xolair under the microscope: how well does it work for nasal polyps in real life?

NCT ID NCT05626257

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how safe and effective Xolair is for adults with chronic rhinosinusitis and nasal polyps when used in routine care. 135 patients who were already prescribed Xolair were followed to track side effects and changes in symptoms. The goal was to see how the drug performs outside of strict clinical trial settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Xolair (omalizumab)
What this could lead to: If successful, this could confirm that Xolair is a safe and effective option for managing nasal polyps in everyday medical practice.
What could go wrong: This is a post-marketing surveillance study, not a controlled trial, so results may be less definitive. It also does not test a new treatment, just monitors existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Contacts and locations

Locations

Novartis Investigative Site

Anyang-si, Gyeonggi-do, 14068, South Korea
Novartis Investigative Site

Bundang Gu, Gyeonggi-do, 13620, South Korea
Novartis Investigative Site

Uijeongbu-si, Gyeonggi-do, 11759, South Korea
Novartis Investigative Site

Incheon, Korea, 405 760, South Korea
Novartis Investigative Site

Seoul, Korea, 03080, South Korea
Novartis Investigative Site

Seoul, Korea, 03312, South Korea
Novartis Investigative Site

Seoul, Korea, 07061, South Korea
Novartis Investigative Site

Seoul, Korea, 08308, South Korea
Novartis Investigative Site

Seoul, Yangcheon gu, 07985, South Korea
Novartis Investigative Site

Daegu, 705 718, South Korea
Novartis Investigative Site

Gyeonggi-do, 14353, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 06351, South Korea
Novartis Investigative Site

Seoul, 07804, South Korea
Novartis Investigative Site

Seoul, 2447, South Korea
Novartis Investigative Site

Suwon, 16247, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.